Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis.
The long-acting somatostatin analogue SMS 201-995 has been used efficaciously in the therapy of metastatic carcinoid tumor, vasoactive intestinal peptide producing islet cell carcinoma, acromegaly, and TSH secreting pituitary tumors. We report the development of a gallstone in a patient treated for 23 months with a long acting somatostatin analogue for a metastatic carcinoid tumor. Symptomatic improvement and a reduction in the urinary excretion of 5-hydroxyindoleacetic acid occurred. There was no evidence of a gallstone on ultrasound and CT scan of the abdomen prior to somatostatin therapy. A progressively enlarging, asymptomatic gallstone developed during therapy.
Roti
E
E
Centro per lo Studio, Prevenzione, Diagnosi e Cura delle Tireopatie, Università degli Studi di Parma, Italy.
Minelli
R
R
Gardini
E
E
Salvi
M
M
Bianconi
L
L
Balducci
L
L
Manfredi
A
A
Braverman
L E
LE
D002276:Carcinoid Tumor / Q000188:drug therapy*; D002769:Cholelithiasis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D015282:Octreotide / Q000009:adverse effects* / Q000627:therapeutic use
D015282:Octreotide